Risperidone and aripiprazole may reduce irritability symptoms, while lurasidone probably results in little to no difference in children with autism. There is significant uncertainty about the effects ...

Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

To explore the views and experiences of adolescents and youth who engaged with (i.e. were approached for participation) or participated in HIV research in low-and middle-income countries. To develop a ...

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of exercise interventions for work-related complaints of the arm, neck or shoulder (CANS) ...

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.

Compared with placebo, PPIs may have no effect on the presence of global symptoms of dyspepsia and probably result in a slight reduction in global symptoms of dyspepsia scales. PPI probably reduces ...

Level III sleep studies may result in little to no difference in clinical outcomes when compared to Level 1 sleep studies in people with suspected OSA. Level IV sleep studies may not increase ...

The evidence does not currently support a clear benefit or harm for routine intravenous thrombolysis amongst people receiving endovascular thrombectomy. Amongst participants receiving endovascular ...

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions. Borys F, Sibrecht G, ...

Country search requires JavaScript to work.

Treinta ensayos de 25 fármacos, que incluían a 516 participantes, contribuyeron con datos a la revisión. Se ha propuesto que los fármacos presentan diversos modos de acción y los resultados se ...

新的研究应该聚焦于以患者为中心的结局来阐明罗格列酮治疗的效益风险比。所有研究（发表和未发表）的安全数据和不良事件均应该向公众开放获取。 糖尿病长期以来一直被认为是一个强大的 ...